Rxo (RXO) Cost of Revenue (2021 - 2026)

Rxo (RXO) has reported Cost of Revenue for 6 consecutive years, with $1.2 billion the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1.2 billion, up 1.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 15.18% YoY), and the FY2025 annual result was $4.6 billion, up 29.34% from the prior year.
• Cost of Revenue was $1.2 billion for Q1 2026 at Rxo, down from $1.2 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $1.4 billion in Q4 2024 and troughed at $699.0 million in Q1 2024.
• Average Cost of Revenue over 5 years is $937.5 million, with a median of $857.0 million recorded in 2022.
• Year-over-year, Cost of Revenue slipped 25.66% in 2023 and soared 82.64% in 2024.
• Over 5 years, Cost of Revenue stood at $842.0 million in 2022, then slipped by 11.76% to $743.0 million in 2023, then soared by 82.64% to $1.4 billion in 2024, then decreased by 11.35% to $1.2 billion in 2025, then fell by 2.66% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.